



Certain specialty medication precertification requests may require additional documentation

Refer to the [Louisiana Medicaid Preferred Drug List/Non-Preferred Drug List \(PDL/NPDL\)](#) for outpatient retail pharmacy coverage. This communication pertains to medical policy only.

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman, Italic

Formatted: Font: (Default) Times New Roman

As part of our ongoing quality improvement efforts, Healthy Blue is updating our precertification processes for certain specialty medications. Effective [August 1, 2021], we may request additional documentation billed under the medical benefit for impacted medications to determine medical necessity.

Upon request, providers shall submit documentation from the member’s medical record for each policy question flagged for documentation. A denial may result if documentation does not support medical necessity.

Should you have any questions, please refer to the *Clinical Criteria* policy website at <https://www.anthem.com/ms/pharmacyinformation/clinicalcriteria/home.html> for specific medication criteria details.

Impacted policy	Impacted medication(s)
ING-CC-0153: Adakveo (crizanlizumab)	Adakveo
ING-CC-0065: Agents for Hemophiilia A and von Willebrand Disease	Advate, Adynovate, Afstyla, Alphanate, Eloctate, Esperoct, Helixate FS, Hemlibra, Hemofil-M, Humate-P, Jivi, Koate-DVI, Kogenate FS, Kovaltry, Monoclalte-P, Novoeight, Nuwiq, Obizur, Recombinate, Wilate, Xyntha
ING-CC-0148: Agents for Hemophilia B	Alphanine SD, Alprolix, Bebulin, Benefix, Idelvion, Ixinity, Mononine, Profilnine SD, Rebinyn, Rixubis
ING-CC-0073: Alpha-1 Proteinase Inhibitor Therapy	Aralast, Glassia, Prolastin-C, Zemaira
ING-CC-0028: Benlysta (belimumab)	Benlysta
ING-CC-0012: Brineura (cerliponase alfa)	Brineura
ING-CC-0041: Complement Inhibitors	Soliris, Ultomiris
ING-CC-0081: Crysvita (burosumab-twza)	Crysvita
ING-CC-0035: Duopa (carbidopa and levodopa enteral suspension)	Duopa
ING-CC-0029: Dupixent (dupilumab)	Dupixent
ING-CC-0069: Egrifta (tesamorelin)	Egrifta
ING-CC-0173: Enspryng (satralizumab-mwge)	Enspryng
ING-CC-0051: Enzyme Replacement Therapy for Gaucher Disease	Cerezyme, Elelyso, Vpriv
ING-CC-0021: Fabrazyme (agalsidase beta)	Fabrazyme
ING-CC-0068: Growth hormone	Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive

<https://providers.healthyblue.com>

Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.
BLA-NL-0323-21 [April 2021]

ING-CC-0034: Hereditary Angioedema Agents	Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest, Takhzyro
ING-CC-0188: Imcivree (setmelanotide)	Imcivree
ING-CC-0070: Jetrea (ocriplasmin)	Jetrea
ING-CC-0037: Kanuma (sebelipase alfa)	Kanuma
ING-CC-0057: Krystexxa (peglicase)	Krystexxa
ING-CC-0018: Lumizyme (alglucosidase alfa)	Lumizyme
ING-CC-0111: Nplate (romiplostim)	Nplate
ING-CC-0082: Onpattro (patisiran)	Onpattro
ING-CC-0049: Radicava (edaravone)	Radicava
ING-CC-0156: Reblozyl (luspatercept)	Reblozyl
ING-CC-0159: Scenesse (afamelanotide)	Scenesse
ING-CC-0149: Select Clotting Agents for Bleeding Disorders	Feiba, Novoseven
ING-CC-0079: Strensiq (asfotase alfa)	Strensiq
ING-CC-0008: Subcutaneous Hormonal Implants	Testopel
ING-CC-0084: Tegsedi (inotersen)	Tegsedi
ING-CC-0162: Tepezza (teprotumumab-trbw)	Tepezza
ING-CC-0170: Uplizna (inebilizumab)	Uplizna
ING-CC-0017: Xiaflex (clostridial collagenase histolyticum) injection	Xiaflex